Bradykinin Receptor 2 Antibodies
Bradykinin receptor 2 (B2) are activated by the endogenous peptides bradykinin (BK) and Lys-BK (kallidin). Bradykinin is a vasoactive, pain inducing and pro-inflammatory kinin released during acute inflammation, and its receptors, B1 and B2, are expressed on eosinophils, and neutrophils.The B2 antagonist Icatibant (Firazyr) is approved in the US and EU for the treatment of acute attacks of hereditary angioedema. B2 receptor desensitization, β-arrestin recruitment and internalization are regulated by phosphorylation of carboxyl-terminal serine366/threonine369 (pS366/pT369-B2) and threonine372/serine373 (pT372/pS373-B2). This nomenclature refers to the human B2 receptor. This phosphorylation motif is highly conserved across species but corresponds to pS367/pT370-B2 and pT373/pS374-B2 in mice and pS371/pT374-B2 and pT377/pS378-B2 in rats. For more information on B2 pharmacology please refer to the IUPHAR database. For further reading refer to:
Coulson J, Couture R, Faussner A, Gobeil Jr F, Leeb-Lundberg F, Marceau F, Muller-Esterl W, Pettibone D, Zuraw B. Bradykinin receptors in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide to Pharmacology CITE. 2019; 2019(4). Available from: https://doi.org/10.2218/gtopdb/F10/2019.4.